This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

This database contains 46 studies, archived under the term: "Sweden"

Click here to filter this large number of results.

Reduced prostaglandin F2 alpha release from blood mononuclear leukocytes after oral supplementation of omega3 fatty acids: the OmegAD study
Omega-3 fatty acids, e.g., dokosahexaenoic acid (DHA) and eikosapentaenoic acid (EPA), ameliorate inflammatory reactions by various mechanisms, but the role of prostaglandins remains unclear. Our aim was to determine if dietary supplementation with a DHA-rich fish oil influenced the release of PGF(2alpha) from peripheral blood mononuclear cells (PBMC). In the OmegAD study, 174 Alzheimer disease […]

Quality of life and the effect of memantine in dementia with lewy bodies and Parkinson’s disease dementia
Aim: To investigate quality of life (QOL) and the effect of memantine treatment in patients with Lewy body dementias.; Methods: A secondary analysis of a randomized controlled study in 70 patients with Parkinson’s disease dementia (PDD) or dementia with Lewy bodies (DLB) over 24 weeks using caregiver-rated QOL-Alzheimer’s disease (AD) in domains according to the […]

Long-term effects of galantamine treatment on brain functional activities as measured by PET in Alzheimer’s disease patients
The effects of galantamine (16 to 24 mg/day) treatment on brain functional activities (blood flow and glucose metabolism) were examined in 18 patients with mild Alzheimer’s disease (AD) in relation to brain acetylcholinesterase (AChE) activity and nicotinic receptors and cognitive function. The study consisted of an initial double-blind phase of three months (short-term) followed by […]

Phenserine efficacy in Alzheimer’s disease
To gather preliminary evidence in Alzheimer’s disease (AD) for the efficacy of phenserine, a non-competitive acetylcholinesterase inhibitor that has independent modulatory effects on amyloid-β generation, a 12-week comparison of patients receiving phenserine (10 and 15 mg BID) or placebo was conducted under double-blind conditions. Patients who completed 12 weeks of the double-blind before others were […]

The effect of memantine on sleep behaviour in dementia with Lewy bodies and Parkinson’s disease dementia
Objective: Two common and characteristic sleep disturbances have been described in dementia with Lewy bodies (DLB) and Parkinson’s disease dementia (PDD); excessive daytime sleepiness and REM sleep behaviour disorder (RBD). This study is an analysis of a secondary outcome measure of a larger study already reported, aimed to determine whether memantine has an effect on […]

Using Talking Mats to support communication in persons with Huntington’s disease
Background: Many individuals with Huntington’s disease experience reduced functioning in cognition, language and communication. Talking Mats is a visually based low technological augmentative communication framework that supports communication in people with different cognitive and communicative disabilities.; Aims: To evaluate Talking Mats as a communication tool for people in the later stages of Huntington’s disease.; Methods& […]

Different cholinesterase inhibitor effects on CSF cholinesterases in Alzheimer patients
Background: The current study aimed to compare the effects of different cholinesterase inhibitors on acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) activities and protein levels, in the cerebrospinal fluid (CSF) of Alzheimer disease (AD) patients.; Methods and Findings: AD patients aged 50-85 years were randomized to open-label treatment with oral rivastigmine, donepezil or galantamine for 13 weeks. […]

Long-term rivastigmine treatment in a routine clinical setting
Objective: The aim of the study was to observe the effects of long-term rivastigmine treatment in patients with mild to moderate Alzheimer’s disease (AD) in a routine clinical setting.; Methods: This was a prospective, open-label, observational, multicentre, non-randomized study. Outcome measures included the Mini Mental State Examination (MMSE), the Clinician’s Interview-Based Impression of Change (CIBIC) […]

The effect of a high-intensity functional exercise program on activities of daily living: a randomized controlled trial in residential care facilities
Objectives: To evaluate whether a high-intensity functional weight-bearing exercise program reduces dependency in activities of daily living (ADLs) in older people living in residential care facilities, focusing on people with dementia.; Design: Randomized, controlled trial.; Setting: Nine residential care facilities.; Participants: One hundred ninety-one older people dependent in ADLs and with a Mini-Mental State Examination […]

Effects of omega-3 fatty acids on inflammatory markers in cerebrospinal fluid and plasma in Alzheimer’s disease: the OmegAD study
Background: omega-3 fatty acids (omega-3 FAs) found in dietary fish or fish oils are anti-inflammatory agents that may influence Alzheimer’s disease (AD).; Objective: To study the effects of dietary omega-3 FA supplementation on inflammatory markers in cerebrospinal fluid (CSF) and plasma from patients with mild to moderate AD.; Methods: Thirty-five patients (70.3 +/- 8.2 years) […]

Try searching our database by another keyword...

To make a new query of the database, please enter your search terms below:

�

Contact Us